Parabilis reveals IPO plans the day after Regeneron deal as listings heat up

Parabilis Medicines has filed for an IPO seeking up to $100 million just one day after announcing a major strategic collaboration with Regeneron worth up to $2.3 billion.

Under the Regeneron deal, Parabilis will receive $50 million upfront and Regeneron has committed to invest $75 million in Parabilis’s next equity financing, which is being structured as part of the IPO raise.

The biotech plans to use IPO proceeds to advance its lead helicon‑peptide candidate zolucatetide (FOG‑001) into a global registrational Phase III trial in desmoid tumors, expand its broader pipeline, and fund its Helicon platform and general corporate purposes.

Parabilis will list on Nasdaq under the ticker symbol PBLS, with underwriters including Leerink Partners, BofA Securities, and Evercore ISI.

The IPO filing underscores a broader uptick in biotech listings, as investors show renewed appetite for companies with validated platforms and corporate partnerships from large‑pharma partners like Regeneron.